The result of the Meta-analysis of three studies (29, 30, 44) demonstrated that SGLT2 inhibitors significantly reduced the number of first hospitalization for heart failure in patients with HFpEF compared to placebo (HR: 0.71, 95% CI: [0.62, 0.83], P < 0.00001, I2 = 0%). This evidence concerns the gene SLC5A2 and heart failure.